CClinicalTrials.gg
CompletedNCT07260084Updated Dec 3, 2025

Prognostic Impact of Frailty in Cardiogenic Shock

An observational study in Cardiogenic Shock, Frailty and Age, sponsored by Samsung Medical Center. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-03.

Sponsored by Samsung Medical Center · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
207,419
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to show prognostic impact of frailty in cardiogenic shock according to age. The main questions it aims to answer are:

  • Can frailty successfully predict outcomes in cardiogenic shock?
  • Whether the impact of frailty would differ with age in cardiogenic shock?
02

Conditions studied

  • Cardiogenic Shock
  • Frailty
  • Age

Keywords

  • frailty
  • cardiogenic shock
  • Hospital Frailty Risk Score
  • Age
03

In context

Shock, Cardiogenic

277 studies on the registry are indexed under Shock, Cardiogenic; 127 are open to participants now.

This study's enrollment of 207,419 is above the median of 200 across 142 observational studies indexed under Shock, Cardiogenic.

Browse Shock, Cardiogenic studies →

Lead sponsor

Samsung Medical Center is the lead sponsor of 980 studies on the registry; 146 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults aged ≥18 years who were admitted to the intensive care unit (ICU) of tertiary hospitals and were diagnosed with CS

Inclusion criteria

  • Adults aged ≥18 years who were admitted to the intensive care unit (ICU) of tertiary hospitals and were diagnosed with CS

Exclusion criteria

Exclusion Criteria:

  • Patients diagnosed with anaphylaxis
  • Patients with a documented history of shock in the year before the index admission
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
207,419 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. In-hospital all-cause mortality

    Death from any cause occurring during the index hospitalization for cardiogenic shock. Number of participants with the event was measured

    Time frame: During index hospitalization for cardiogenic shock (up to hospital discharge)

Secondary outcomes

  1. Heart failure-related rehospitalization

    Any inpatient admission with a primary or secondary diagnosis of heart failure (ICD-10 I50.x), identified from claims data and prescription records.Number of participants with the event was measured.

    Time frame: From index hospitalization until 15 years of follow-up.

  2. Cognitive impairment

    New-onset cognitive dysfunction after discharge, defined using ICD-10 codes (R41.x for memory disturbance, F06.7 for mild cognitive disorder) or new diagnosis of dementia (F00-F03, G30) or prescription of anti-dementia medications (donepezil, rivastigmine, galantamine, memantine). Number of participants with event was measured

    Time frame: From index hospitalization until 15 years of follow-up.

  3. Mental health problems

    Composite of new-onset psychiatric diagnoses after discharge including 6 domains defined using ICD-10 codes. Domains include depression (ICD-10 F32-F33), anxiety disorders (F41.x), somatization disorder (F45.x), stress-related disorders (F43.x), sleep disorders (G47.x), and substance use disorders (F10-F19). Diagnostic codes supported by prescription data (e.g., antidepressants, anxiolytics). Number of participants with the event was measured.

    Time frame: From index hospitalization until 15 years of follow-up.

  4. Long-term all-cause mortality

    Death from any cause, identified with the Statistics Korea nationwide death registry. Number of participants with the event was measured.

    Time frame: From index hospitalization until 15 years of follow-up.

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07260084
Lead sponsor
Samsung Medical Center
Responsible party
Ki Hong Choi (Professor, Samsung Medical Center) — Principal investigator
First posted
Dec 3, 2025
Start date
Jan 1, 2012
Primary completion
Oct 31, 2023
Completion
Oct 31, 2023
Last update
Dec 3, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion